Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Carcinoma, Squamous Cell | 8 | 2024 | 4069 | 1.980 |
Why?
|
Multiple Myeloma | 29 | 2024 | 5192 | 1.490 |
Why?
|
Skin Neoplasms | 8 | 2022 | 5857 | 1.330 |
Why?
|
Cyclin D1 | 2 | 2024 | 453 | 0.810 |
Why?
|
Chromosome Aberrations | 9 | 2023 | 1780 | 0.720 |
Why?
|
Neoplasm Staging | 6 | 2022 | 11254 | 0.690 |
Why?
|
Peripheral Nerves | 1 | 2020 | 492 | 0.540 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2019 | 687 | 0.470 |
Why?
|
Plasma Cells | 8 | 2017 | 599 | 0.460 |
Why?
|
High-Throughput Nucleotide Sequencing | 5 | 2019 | 3666 | 0.430 |
Why?
|
Sequence Analysis, RNA | 1 | 2020 | 2038 | 0.410 |
Why?
|
Neoplasms, Multiple Primary | 3 | 2021 | 594 | 0.390 |
Why?
|
Thalidomide | 5 | 2017 | 886 | 0.380 |
Why?
|
Paraproteinemias | 4 | 2016 | 252 | 0.370 |
Why?
|
Cyclin D2 | 2 | 2024 | 98 | 0.350 |
Why?
|
Mutation, Missense | 1 | 2019 | 2593 | 0.350 |
Why?
|
Prognosis | 21 | 2022 | 30022 | 0.340 |
Why?
|
Head and Neck Neoplasms | 1 | 2024 | 2923 | 0.330 |
Why?
|
Genome, Human | 2 | 2021 | 4450 | 0.300 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 3633 | 0.290 |
Why?
|
Dexamethasone | 5 | 2020 | 1965 | 0.270 |
Why?
|
Colorectal Neoplasms | 6 | 2023 | 6971 | 0.260 |
Why?
|
DNA | 1 | 2019 | 7211 | 0.250 |
Why?
|
Syndecan-1 | 2 | 2018 | 163 | 0.250 |
Why?
|
Gene Expression Profiling | 10 | 2024 | 9510 | 0.250 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2024 | 5422 | 0.240 |
Why?
|
Gene Expression Regulation, Neoplastic | 13 | 2022 | 8634 | 0.240 |
Why?
|
Loss of Heterozygosity | 2 | 2020 | 663 | 0.240 |
Why?
|
DNA Copy Number Variations | 5 | 2021 | 2046 | 0.230 |
Why?
|
Cyclin D | 1 | 2024 | 72 | 0.230 |
Why?
|
Neoplasm, Residual | 2 | 2022 | 1019 | 0.220 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2019 | 3620 | 0.220 |
Why?
|
In Situ Hybridization, Fluorescence | 4 | 2019 | 2524 | 0.220 |
Why?
|
Gene Dosage | 4 | 2016 | 1221 | 0.220 |
Why?
|
Immunophenotyping | 7 | 2016 | 1866 | 0.200 |
Why?
|
DNA Methylation | 5 | 2022 | 4421 | 0.200 |
Why?
|
Amiloride | 2 | 2022 | 116 | 0.200 |
Why?
|
Algorithms | 2 | 2020 | 14154 | 0.200 |
Why?
|
Monoclonal Gammopathy of Undetermined Significance | 2 | 2015 | 179 | 0.200 |
Why?
|
Chromosomes, Human | 2 | 2014 | 444 | 0.190 |
Why?
|
Tumor Suppressor Protein p53 | 3 | 2022 | 2952 | 0.190 |
Why?
|
KCNQ2 Potassium Channel | 1 | 2021 | 19 | 0.190 |
Why?
|
Breathing Exercises | 1 | 2021 | 59 | 0.180 |
Why?
|
Lymphoma, T-Cell, Peripheral | 1 | 2022 | 125 | 0.180 |
Why?
|
Thrombocythemia, Essential | 1 | 2022 | 114 | 0.180 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2022 | 168 | 0.180 |
Why?
|
Aged, 80 and over | 13 | 2022 | 59686 | 0.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 3 | 2018 | 1755 | 0.180 |
Why?
|
Retrospective Studies | 9 | 2022 | 81801 | 0.180 |
Why?
|
Humans | 60 | 2024 | 768393 | 0.170 |
Why?
|
Athletic Performance | 1 | 2021 | 113 | 0.170 |
Why?
|
Osteogenesis | 2 | 2017 | 1295 | 0.170 |
Why?
|
Chromosome Breakpoints | 1 | 2019 | 93 | 0.170 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4120 | 0.170 |
Why?
|
Leukemia, Plasma Cell | 1 | 2019 | 46 | 0.170 |
Why?
|
Lung Neoplasms | 1 | 2024 | 13576 | 0.160 |
Why?
|
Drug Synergism | 3 | 2017 | 1762 | 0.160 |
Why?
|
Serum Amyloid P-Component | 1 | 2018 | 46 | 0.160 |
Why?
|
Hematologic Neoplasms | 2 | 2022 | 1905 | 0.150 |
Why?
|
Nucleotidyltransferases | 1 | 2020 | 242 | 0.150 |
Why?
|
Mesenchymal Stem Cells | 2 | 2019 | 1671 | 0.150 |
Why?
|
Karyotyping | 1 | 2019 | 1173 | 0.140 |
Why?
|
Thiadiazoles | 1 | 2017 | 63 | 0.140 |
Why?
|
Antigens, CD34 | 1 | 2019 | 656 | 0.140 |
Why?
|
Tumor Burden | 2 | 2020 | 1913 | 0.140 |
Why?
|
Proto-Oncogene Proteins c-pim-1 | 1 | 2016 | 31 | 0.140 |
Why?
|
Immunoglobulins | 1 | 2020 | 855 | 0.140 |
Why?
|
Telomere | 1 | 2023 | 943 | 0.130 |
Why?
|
RNA, Messenger | 5 | 2020 | 12805 | 0.130 |
Why?
|
Gamma Rays | 1 | 2017 | 319 | 0.130 |
Why?
|
Opportunistic Infections | 1 | 2018 | 375 | 0.130 |
Why?
|
MicroRNAs | 5 | 2020 | 3804 | 0.130 |
Why?
|
Tumor Cells, Cultured | 2 | 2020 | 6132 | 0.120 |
Why?
|
Incidental Findings | 1 | 2020 | 698 | 0.120 |
Why?
|
Antibody Formation | 1 | 2020 | 1393 | 0.120 |
Why?
|
Lectins, C-Type | 1 | 2018 | 591 | 0.120 |
Why?
|
Protective Agents | 1 | 2016 | 150 | 0.120 |
Why?
|
Immunoglobulin Light Chains | 1 | 2016 | 289 | 0.120 |
Why?
|
Adipogenesis | 1 | 2017 | 371 | 0.120 |
Why?
|
Sensitivity and Specificity | 2 | 2021 | 14737 | 0.120 |
Why?
|
Systems Integration | 1 | 2016 | 430 | 0.120 |
Why?
|
Genomics | 6 | 2016 | 5916 | 0.120 |
Why?
|
Immunoassay | 1 | 2018 | 745 | 0.120 |
Why?
|
Diuretics | 1 | 2017 | 612 | 0.110 |
Why?
|
Pancreaticoduodenectomy | 1 | 2018 | 516 | 0.110 |
Why?
|
Interphase | 1 | 2014 | 227 | 0.110 |
Why?
|
Meningioma | 1 | 2023 | 1221 | 0.110 |
Why?
|
Pancreatic Neoplasms | 3 | 2018 | 5443 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1794 | 0.110 |
Why?
|
Aged | 20 | 2021 | 171562 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 7 | 2021 | 16028 | 0.110 |
Why?
|
Plasmacytoma | 1 | 2014 | 170 | 0.110 |
Why?
|
Meningeal Neoplasms | 1 | 2023 | 1253 | 0.110 |
Why?
|
Burkitt Lymphoma | 1 | 2015 | 337 | 0.110 |
Why?
|
Cell Line, Tumor | 10 | 2020 | 17135 | 0.110 |
Why?
|
Interleukin-8 | 1 | 2016 | 705 | 0.110 |
Why?
|
RNA Processing, Post-Transcriptional | 1 | 2015 | 393 | 0.100 |
Why?
|
Phagocytosis | 1 | 2018 | 1530 | 0.100 |
Why?
|
Nanotechnology | 1 | 2018 | 714 | 0.100 |
Why?
|
Male | 24 | 2022 | 364902 | 0.100 |
Why?
|
Open Reading Frames | 1 | 2015 | 812 | 0.100 |
Why?
|
Drainage | 1 | 2018 | 1184 | 0.100 |
Why?
|
Developmental Disabilities | 1 | 2021 | 1516 | 0.100 |
Why?
|
Myelodysplastic Syndromes | 1 | 2022 | 1399 | 0.100 |
Why?
|
Rectal Neoplasms | 1 | 2021 | 1188 | 0.100 |
Why?
|
RNA, Untranslated | 1 | 2015 | 457 | 0.100 |
Why?
|
Cytogenetic Analysis | 3 | 2022 | 270 | 0.100 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 620 | 0.100 |
Why?
|
Bone Marrow Cells | 1 | 2019 | 2414 | 0.100 |
Why?
|
Female | 24 | 2022 | 397089 | 0.090 |
Why?
|
Antineoplastic Agents | 3 | 2022 | 13697 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 18048 | 0.090 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2016 | 716 | 0.090 |
Why?
|
Protein Kinase Inhibitors | 2 | 2016 | 5708 | 0.090 |
Why?
|
Bone Marrow | 1 | 2019 | 2929 | 0.080 |
Why?
|
Pilot Projects | 1 | 2022 | 8731 | 0.080 |
Why?
|
Flow Cytometry | 3 | 2015 | 5900 | 0.080 |
Why?
|
Phenotype | 8 | 2021 | 16721 | 0.080 |
Why?
|
Risk | 1 | 2021 | 9636 | 0.080 |
Why?
|
Base Sequence | 1 | 2019 | 12422 | 0.080 |
Why?
|
Sequence Analysis, DNA | 1 | 2019 | 4775 | 0.080 |
Why?
|
Drug Resistance, Neoplasm | 4 | 2016 | 5336 | 0.080 |
Why?
|
Amyloidosis | 1 | 2016 | 879 | 0.080 |
Why?
|
Early Detection of Cancer | 1 | 2023 | 3236 | 0.080 |
Why?
|
Hematopoiesis | 1 | 2017 | 2058 | 0.080 |
Why?
|
Immunotherapy | 1 | 2024 | 4738 | 0.070 |
Why?
|
Computational Biology | 2 | 2016 | 3543 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2016 | 2460 | 0.070 |
Why?
|
B-Lymphocytes | 3 | 2017 | 4785 | 0.070 |
Why?
|
TOR Serine-Threonine Kinases | 1 | 2016 | 2066 | 0.070 |
Why?
|
Chromosomes, Human, Pair 11 | 2 | 2020 | 411 | 0.070 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2016 | 2884 | 0.070 |
Why?
|
Middle Aged | 18 | 2023 | 223491 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2022 | 9433 | 0.070 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2017 | 2890 | 0.070 |
Why?
|
C-Reactive Protein | 1 | 2018 | 3857 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 1558 | 0.070 |
Why?
|
Gene Frequency | 3 | 2020 | 3617 | 0.070 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 957 | 0.070 |
Why?
|
Skin | 1 | 2020 | 4499 | 0.070 |
Why?
|
Ikaros Transcription Factor | 2 | 2020 | 233 | 0.070 |
Why?
|
Bone and Bones | 1 | 2016 | 2589 | 0.060 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2015 | 1077 | 0.060 |
Why?
|
Lymphocyte Activation | 1 | 2016 | 5496 | 0.060 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2846 | 0.060 |
Why?
|
Comparative Genomic Hybridization | 2 | 2016 | 474 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15455 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2021 | 7880 | 0.060 |
Why?
|
Graft vs Host Disease | 1 | 2016 | 3044 | 0.060 |
Why?
|
Risk Factors | 6 | 2022 | 74962 | 0.050 |
Why?
|
CpG Islands | 2 | 2021 | 1209 | 0.050 |
Why?
|
Melphalan | 2 | 2016 | 421 | 0.050 |
Why?
|
Translocation, Genetic | 2 | 2022 | 1395 | 0.050 |
Why?
|
Cell Differentiation | 2 | 2017 | 11668 | 0.050 |
Why?
|
Monosomy | 1 | 2023 | 52 | 0.050 |
Why?
|
Propidium | 1 | 2022 | 42 | 0.050 |
Why?
|
Annexin A5 | 1 | 2022 | 104 | 0.050 |
Why?
|
Alternative Splicing | 2 | 2019 | 1093 | 0.050 |
Why?
|
Cell Survival | 3 | 2017 | 5792 | 0.050 |
Why?
|
Osteoclasts | 2 | 2016 | 712 | 0.050 |
Why?
|
Clone Cells | 2 | 2016 | 1671 | 0.050 |
Why?
|
Microarray Analysis | 2 | 2016 | 753 | 0.050 |
Why?
|
Cell Proliferation | 4 | 2020 | 10478 | 0.050 |
Why?
|
Cytogenetics | 1 | 2022 | 198 | 0.050 |
Why?
|
Coculture Techniques | 2 | 2016 | 1342 | 0.050 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 3827 | 0.050 |
Why?
|
Oligonucleotide Array Sequence Analysis | 3 | 2016 | 3794 | 0.050 |
Why?
|
Risk Assessment | 1 | 2022 | 24318 | 0.050 |
Why?
|
Prospective Studies | 2 | 2024 | 54920 | 0.050 |
Why?
|
Cluster Analysis | 2 | 2021 | 2728 | 0.050 |
Why?
|
Respiratory Muscles | 1 | 2021 | 144 | 0.040 |
Why?
|
Respiratory Therapy | 1 | 2021 | 125 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2016 | 4365 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 3 | 2016 | 6541 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2018 | 65379 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 2017 | 11854 | 0.040 |
Why?
|
Apoptosis | 4 | 2017 | 9516 | 0.040 |
Why?
|
Chromosomal Instability | 1 | 2021 | 178 | 0.040 |
Why?
|
Disease Progression | 5 | 2016 | 13646 | 0.040 |
Why?
|
Stromal Cells | 2 | 2016 | 1337 | 0.040 |
Why?
|
Cell Separation | 2 | 2016 | 1726 | 0.040 |
Why?
|
Gene Duplication | 1 | 2021 | 315 | 0.040 |
Why?
|
Genes, p53 | 1 | 2022 | 716 | 0.040 |
Why?
|
Chromosomes, Human, Pair 6 | 1 | 2020 | 370 | 0.040 |
Why?
|
Caspases | 1 | 2022 | 881 | 0.040 |
Why?
|
Interferon Regulatory Factors | 1 | 2020 | 268 | 0.040 |
Why?
|
Polyadenylation | 1 | 2020 | 114 | 0.040 |
Why?
|
Genetic Association Studies | 2 | 2019 | 2742 | 0.040 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2017 | 3617 | 0.040 |
Why?
|
Unfolded Protein Response | 1 | 2020 | 239 | 0.040 |
Why?
|
Survival Rate | 3 | 2018 | 12870 | 0.040 |
Why?
|
Dystonia | 1 | 2021 | 378 | 0.040 |
Why?
|
Mutation | 5 | 2021 | 30228 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2022 | 1703 | 0.030 |
Why?
|
Receptors, Purinergic P2Y | 1 | 2016 | 23 | 0.030 |
Why?
|
Microsatellite Instability | 1 | 2021 | 726 | 0.030 |
Why?
|
Signal Transduction | 5 | 2020 | 23631 | 0.030 |
Why?
|
Gene Knockout Techniques | 1 | 2020 | 808 | 0.030 |
Why?
|
Aspergillosis | 1 | 2018 | 242 | 0.030 |
Why?
|
Cell Cycle | 2 | 2016 | 2938 | 0.030 |
Why?
|
Up-Regulation | 2 | 2016 | 4142 | 0.030 |
Why?
|
Cohort Studies | 1 | 2019 | 41795 | 0.030 |
Why?
|
LDL-Receptor Related Proteins | 1 | 2016 | 119 | 0.030 |
Why?
|
Cell Dedifferentiation | 1 | 2017 | 124 | 0.030 |
Why?
|
Genes, Tumor Suppressor | 1 | 2020 | 1064 | 0.030 |
Why?
|
Glycosyltransferases | 1 | 2016 | 114 | 0.030 |
Why?
|
Cerebral Palsy | 1 | 2021 | 479 | 0.030 |
Why?
|
Candidiasis | 1 | 2018 | 367 | 0.030 |
Why?
|
Adult | 10 | 2021 | 223640 | 0.030 |
Why?
|
Cyclin D3 | 1 | 2015 | 54 | 0.030 |
Why?
|
Motor Neurons | 1 | 2021 | 872 | 0.030 |
Why?
|
Mice | 6 | 2019 | 82017 | 0.030 |
Why?
|
E-Box Elements | 1 | 2014 | 20 | 0.030 |
Why?
|
Thiophenes | 1 | 2019 | 569 | 0.030 |
Why?
|
Exons | 1 | 2021 | 2392 | 0.030 |
Why?
|
Chromosomes, Human, Pair 14 | 1 | 2015 | 286 | 0.030 |
Why?
|
Genes, Neoplasm | 1 | 2016 | 370 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 2021 | 1175 | 0.030 |
Why?
|
Protein Processing, Post-Translational | 1 | 2022 | 1967 | 0.030 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 2020 | 1319 | 0.030 |
Why?
|
Tumor Stem Cell Assay | 1 | 2013 | 116 | 0.030 |
Why?
|
Promoter Regions, Genetic | 2 | 2015 | 5801 | 0.030 |
Why?
|
Age of Onset | 1 | 2021 | 3345 | 0.030 |
Why?
|
Antifungal Agents | 1 | 2018 | 759 | 0.030 |
Why?
|
Precursor Cells, B-Lymphoid | 1 | 2014 | 99 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2018 | 12092 | 0.030 |
Why?
|
Morpholines | 1 | 2016 | 584 | 0.030 |
Why?
|
3' Untranslated Regions | 1 | 2015 | 515 | 0.030 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 1409 | 0.030 |
Why?
|
Aminopyridines | 1 | 2016 | 580 | 0.030 |
Why?
|
Animals | 7 | 2019 | 169337 | 0.030 |
Why?
|
Bone Resorption | 1 | 2016 | 727 | 0.030 |
Why?
|
Standard of Care | 1 | 2016 | 570 | 0.020 |
Why?
|
Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 615 | 0.020 |
Why?
|
United States | 1 | 2020 | 73150 | 0.020 |
Why?
|
Principal Component Analysis | 1 | 2014 | 948 | 0.020 |
Why?
|
Integrins | 1 | 2016 | 843 | 0.020 |
Why?
|
Quinolines | 1 | 2016 | 768 | 0.020 |
Why?
|
Prednisone | 1 | 2016 | 1567 | 0.020 |
Why?
|
Membrane Transport Proteins | 1 | 2016 | 1034 | 0.020 |
Why?
|
Demography | 1 | 2015 | 1642 | 0.020 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2015 | 582 | 0.020 |
Why?
|
Nucleic Acid Hybridization | 1 | 2012 | 1305 | 0.020 |
Why?
|
Neoplasm Transplantation | 1 | 2014 | 2017 | 0.020 |
Why?
|
Imidazoles | 1 | 2016 | 1168 | 0.020 |
Why?
|
Immunoglobulin M | 1 | 2015 | 1528 | 0.020 |
Why?
|
Boronic Acids | 1 | 2014 | 915 | 0.020 |
Why?
|
Family | 1 | 2021 | 3208 | 0.020 |
Why?
|
Databases, Genetic | 1 | 2016 | 1748 | 0.020 |
Why?
|
Genetic Markers | 1 | 2016 | 2604 | 0.020 |
Why?
|
Cell Adhesion Molecules | 1 | 2016 | 1614 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1980 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2020 | 4921 | 0.020 |
Why?
|
Benzimidazoles | 1 | 2014 | 864 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3813 | 0.020 |
Why?
|
Preoperative Care | 1 | 2018 | 2258 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2632 | 0.020 |
Why?
|
T-Lymphocytes | 2 | 2016 | 10267 | 0.020 |
Why?
|
Down-Regulation | 1 | 2016 | 2940 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2020 | 4526 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2018 | 4250 | 0.020 |
Why?
|
Pyrazines | 1 | 2014 | 1206 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2013 | 2127 | 0.020 |
Why?
|
RNA Interference | 1 | 2016 | 2836 | 0.020 |
Why?
|
Cell Movement | 1 | 2020 | 5215 | 0.020 |
Why?
|
Seizures | 1 | 2021 | 3000 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1747 | 0.020 |
Why?
|
Remission Induction | 1 | 2013 | 2407 | 0.020 |
Why?
|
Doxorubicin | 1 | 2014 | 2229 | 0.020 |
Why?
|
Survival Analysis | 1 | 2020 | 10117 | 0.020 |
Why?
|
Pyrimidines | 1 | 2019 | 3048 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2016 | 6085 | 0.020 |
Why?
|
Genome-Wide Association Study | 2 | 2016 | 12778 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2015 | 2206 | 0.020 |
Why?
|
Child | 3 | 2021 | 80891 | 0.020 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 1356 | 0.020 |
Why?
|
Disease Models, Animal | 2 | 2016 | 18362 | 0.020 |
Why?
|
Young Adult | 3 | 2018 | 60049 | 0.020 |
Why?
|
Models, Genetic | 1 | 2016 | 3442 | 0.020 |
Why?
|
Phosphorylation | 1 | 2016 | 8326 | 0.020 |
Why?
|
Epilepsy | 1 | 2021 | 3326 | 0.020 |
Why?
|
Trans-Activators | 1 | 2014 | 2856 | 0.010 |
Why?
|
Incidence | 1 | 2023 | 21544 | 0.010 |
Why?
|
Child, Preschool | 2 | 2018 | 42650 | 0.010 |
Why?
|
Drug Therapy, Combination | 1 | 2014 | 6318 | 0.010 |
Why?
|
Adolescent | 3 | 2018 | 89184 | 0.010 |
Why?
|
Recurrence | 1 | 2016 | 8506 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 2911 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2012 | 4622 | 0.010 |
Why?
|
Gene Expression | 1 | 2016 | 7598 | 0.010 |
Why?
|
Antigens, CD | 1 | 2013 | 4031 | 0.010 |
Why?
|
Lung | 1 | 2021 | 10089 | 0.010 |
Why?
|
Circadian Rhythm | 1 | 2013 | 2588 | 0.010 |
Why?
|
Genotype | 1 | 2016 | 13042 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2017 | 19022 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 2014 | 4414 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2013 | 8562 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12558 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2013 | 39407 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2015 | 14784 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2016 | 26411 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2013 | 22296 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2013 | 20224 | 0.010 |
Why?
|
Time Factors | 1 | 2016 | 40272 | 0.010 |
Why?
|
Hematopoietic Stem Cell Transplantation | 1 | 2013 | 5713 | 0.010 |
Why?
|
Infant | 1 | 2016 | 36510 | 0.010 |
Why?
|